<DOC>
	<DOCNO>NCT00511771</DOCNO>
	<brief_summary>To provide tegaserod eligible woman adult patient satisfactory improvement irritable bowel syndrome constipation ( IBS-C ) chronic idiopathic constipation ( CIC ) symptoms available treatment ( ) / patient satisfactory improvement symptom prior tegaserod treatment IBS-C CIC .</brief_summary>
	<brief_title>A Treatment Investigational New Drug ( tIND ) Program Tegaserod Women With Irritable Bowel Syndrome With Constipation With Chronic Idiopathic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>1 . For patient IBSC : Women 1854 year age IBSC accord Rome III criterion . 2 . For patient Chronic Idiopathic Constipation : Women 1854 year age CIC accord Rome III criterion . 3 . Patients satisfactory symptom improvement IBSC CIC symptom available treatment ( ) / patient satisfactory improvement symptom prior tegaserod treatment IBSC CIC . Satisfactory symptom improvement assess patient . 4 . Patients sign informed consent 1 . History current diagnosis cardiovascular ischemic disease ( e.g. , angina pectoris , myocardial infarction , transient ischemic attack stroke include finding suggestive ischemia ECG change ST segment T wave , / Q wave ) 2 . Patients uninvestigated symptom suggestive cardiovascular ischaemic disease chest pain chest discomfort , shortness breath , sudden onset weakness arm legs , difficult talk loss sensation etc 3 . Presence cardiovascular risk factor accord NIH guideline [ NIH Publication No . 013670 ] ( hypertension , hyperlipidemia , diabetes mellitus , active smoking , obesity family history premature coronary heart disease ) assess investigator 4 . Clinical evidence significant ( judged Investigator ) respiratory , cardiovascular , renal , hepaticbiliary , endocrine , psychiatric neurologic disease presence abdominal adhesion 5 . History current eat disorder anorexia bulimia compulsory overeat . 6 . Uncompensated depression anxiety suicidal ideation behavior . 7 . Diagnosis megarectum colon , history intestinal obstruction , congenital anorectal malformation , clinically significant rectocele , evidence intestinal structural abnormality include gastrointestinal resection affect bowel transit evidence intestinal carcinoma , inflammatory bowel disease alarm symptom weight loss , rectal bleeding , anemia 8 . Evidence cathartic colon history drug ( include laxative ) alcohol abuse , Investigator 's opinion , patient likely continue abuse substance tIND program period 9 . Pregnant woman breastfeed woman ; fertile woman currently practice medically approve method contraception 10 . Participating investigational study concurrently within 1 month prior enter tIND program 11 . Hypersensitive tegaserod excipients 12 . Patients tolerability safety concern prior use tegaserod .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Tegaserod , treatment IND , irritable bowel syndrome constipation , IBS-C , chronic idiopathic constipation , CIC , chronic constipation , CC</keyword>
</DOC>